A significant association between the VEGF-A (rs833069) genotype variants and the anatomic response to intravitreal ranibizumab was observed, but no significant difference was found between the genotype of the potential risk polymorphism for the development of AMD and the visual acuity change after treatment with intravitreal ranibizumab. This evidence concerns the gene VEGFA and age-related macular degeneration.